CA
VRTX icon

CastleArk Alternatives’s Vertex Pharmaceuticals VRTX Stock Holding History

CastleArk Alternatives’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-730
Closed -$132K – 288
2021
Q3 		$132K Buy
+730
New +$143K 0.01% 309

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CastleArk Alternatives's VRTX Position: Q4 2021 in Review

CastleArk Alternatives sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 730 shares — an estimated $132K sold.

CastleArk Alternatives first reported a position in VRTX in Q3 2021 and held it in 1 quarter. The position peaked at $132K in Q3 2021. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • CastleArk Alternatives reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 730 Vertex Pharmaceuticals shares in Q4 2021, an estimated $132K.
  • CastleArk Alternatives first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Vertex Pharmaceuticals position peaked at $132K in Q3 2021.
  • 1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.